Newron Pharmaceuticals S.p.A. (0QOI) Q4 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Ladies and gentlemen, welcome to the 2025 results and 2026 Outlook conference call. I am Matilda, the course call operator. I would like to remind you that all participants will be in listen-only mode and the conference is being recorded. The presentation will be followed by a Q&A session. You can register for questions at any time by pressing star and one on your telephone. For operator assistance, please press star and zero. The conference must not be recorded for publication or broadcast. At this time, it's my pleasure to hand over to Stefan Weber, CEO. Please go ahead. Thank you, Mathilde, and good afternoon, everybody in Europe. Good evening, everybody in Asia, and good morning. And at early 6.30, have a good start into the day from Dana Point, California. As usual in the past years, we are spread over the world. The only person right now in our Milan office is the CFO, as he should be. He's sitting on the money that we need to spend in the upcoming period. Our chief medical officer, Ravi Anand, is right now preparing for the SIRS, Schizophrenia International Research Society, conference that starts tomorrow. And I am attending the conference of Cabell at Dana Point. So welcome to this call. I hope you have had a chance to download the slide deck that we are going to guide you through, and I will start with slide number four. So, if we look back at the last 15 months and the period that we are reporting about, and I will then do the outlook for 26 and hand over to Ravi for the new science and on the progress, and then to Roberto for the financials and the AGM-EGM that is upcoming. If we look back, this has really been a period that couldn't have been much better. We practically hit all the click points. We made all the milestones. But what I want to tell you alr...